NIRAPARIB
niraparib 100 mg tablet, 56
NIRAPARIB (14196E)
14196E
Manner of administration:Oral
Restriction
Indication: High grade stage III/IV epithelial ovarian, fallopian tube or primary peritoneal cancer
Treatment phase: Continuation of first-line maintenance therapy (genomic instability without BRCA1/2
gene mutation) in a patient requiring a daily dose of up to 2 tablets
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 5 | DPMQ: $6,637.77 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Zejula | |||||